In this issue:
Optimising the value of lenalidomide maintenance by genetic profiling
Single-cell profiling suggests that proteomic profiles may determine prognosis
All oral front-line ixazomib combo not suitable for NDMM
High-dose melphalan increases mutational burden at relapse
Sequencing T-cell redirection therapies leads to deep and durable responses
Ethical challenges with CAR T-cell therapy allocation
Patients have confidence in treatment but desire more information
IKEMA demonstrates a durable PFS benefit to isatuximab combo
Novel agents do not significantly improve outcomes in t(11;14) disease
Murine myeloma models may lead to precision immunotherapeutics
Please login below to download this issue (PDF)